WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled Phase 2 clinical trial evaluating GX-03 in adults with moderate-to-severe atopic dermatitis….
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
